AbstractDisease OverviewHodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States.DiagnosisHL is composed of two distinct disease entities: classical HL and nodular lymphocyte‐predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups of classical HL.Risk StratificationAn accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography scan, are used to optimize therapy.Risk‐Adapted TherapyInitial therapy for HL patients is based on the histology of the disease, the anatomical stage, and the presence of poor prognostic features. Patients with early‐stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved‐field radiation therapy, while those with advanced‐stage disease receive a longer course of chemotherapy, often without radiation therapy. However, newer agents, including brentuximab vedotin and anti‐programmed death‐1 (PD‐1) antibodies, are now being incorporated into frontline therapy.Management of Relapsed/Refractory DiseaseHigh‐dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD‐1 blockade, non‐myeloablative allogeneic transplant, or participation in a clinical trial should be considered.
Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Aims Increased LV wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 to 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4 chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: CA: 0.90, HCM: 0.93, and HTN/other: 0.92). Conclusion The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.
Abstract P311: Blood Pressure Control And Anti-hypertensive Drug Utilization Among Minorities In A Large Health Care System
Background: Hypertension (HTN) affects almost half of the adults in the US, and most do not have their blood pressure (BP) under control. Minorities and individuals living in rural areas experience health disparities. The goal of this study was to assess the rate of BP control among adults in a large health system that included minorities and adults living in rural areas. Methods: Clinical cohort study of adults with HTN who live in Southeast Minnesota and had at least one outpatient clinic encounter within the Mayo Clinic Health System in the last 12 months (5/2021-5/2022). Data was extracted through the HTN registry of the electronic health record and included age, race, ethnicity, last office BP and any active anti-hypertensives drug use. Results: The overall rate of HTN control among 127,644 individuals with HTN, defined as an office BP < 130/80 mmHg, was 25.7%. The rates of BP control between HTN subjects living in rural (64527, 67.3%) versus urban areas (41285, 32.3 %), were significantly lower at 24.9% vs. 27% respectively, p< 0.001. A total of 8,722 (6.8%) were non-white, including 2640 Black, 1919 Asian, and 2867 Hispanics A total of 5,734 (45%) had a SBP ≥ 140 or DBP ≥ 90 mmHg and 7178 (12.5%) did not have any anti-hypertensives in their medication list. The percentage of White and Asian persons who were not on anti-hypertensives was 12.4% and 12.5%, respectively, while a larger percentage of Black (13.8%) and Hispanic (14%) persons were not (p<0.001). The corresponding percentage was 16.7% among individuals who did not disclose their race (p<0.001). Conclusion: Among hypertensive adults, BP was not at goal in most patients based on their most recent office BP measurement with a higher rate among those living in rural areas. About 12.5% were not on anti-hypertensives with a disproportionate larger percentage of Black and Hispanic compared to White and Asian persons.
Abstract P304: Persistent Use Of Aktiia 24/7 Blood Pressure Monitor Is Associated With Lower Blood Pressure In Hypertensive Patients
Introduction: Cuffless blood pressure (BP) monitors are a promising innovation for hypertension diagnosis and monitoring. Aktiia (Aktiia 24/7 BP Monitor, Aktiia, Switzerland) is a CE-marked, commercially available BP monitor that passively and continually collects BP waveforms via optical sensors at the wrist. After initial cuff calibration, the app displays BP estimates on a smartphone. No data exist on the impact of persistently showing a person their BP data with this device. Hypothesis: If people with hypertension persistently use Aktiia and are exposed to their BP data, there will be a change in behavior resulting in measurably lower BP. Methods: We analyzed the systolic BP (SBP) trends of 838 real-world users (Age 57±11, 14% female) who consistently used Aktiia for 6 months (375±287 app interactions, 3646±1417 cuffless readings per user, and 9±7 cuff readings per user). Users were grouped by the mean monthly SBP (<140 and >140 mmHg) calculated over 6 months. Then, cuff SBP averages were calculated monthly and compared to the SBP average of the first month. A t-test analysis was used to detect the difference in SBP between the first and successive months. Results: Hypertensive users (SBP > 140 mmHg) saw a reduction in SBP of -3.2 mmHg (CI: -0.70, -5.59, p<0.02), beginning at 3 months and sustained through 6 months. For users with SBP < 140 mm Hg, the mean SBP remained unchanged (Fig. 1). Conclusion: Persistent BP monitoring with Aktiia’s cuffless device is associated with a significant, sustained reduction in SBP for hypertensive patients at 6 months. Possible explanations include the Hawthorne effect or intensified treatment.
Abstract P114: Differential Expression Of Angiotensin Ii Receptors In Aorta Of Ela2ko Mice With Abdominal Aortic Aneurysm.
Elastase-2 (ELA-2) enzyme generates angiotensin-II (AngII) in arteries and is implicated in abnormal vascular remodeling in animal models.Our group demonstrated previously that ELA-2 knockout (ELA-2KO) mice were less susceptible to develop an aorta dilation in a response to AngII infusion. In this study, we hypothesize that susceptibility to an aorta dilation and abdominal aortic aneurysm (AAA) is mediated by AngII receptors (AT1 and AT2). Methods: Male wild type (C57bl/6, WT) and ELA-2KO (CELA-2aTm1Bdr) mice were treated with either saline or AngII (2.28g/g/min) for twenty-eight days by subcutaneously mini-pumps infusion. Mice were divided into four groups: WT treated with saline (WT+SAL, n=5), ELA-2KO treated with saline (ELA-2KO+SAL, n=5), WT treated with AngII (WT+AngII,n=5), and ELA-2KO treated with AngII (ELA-2KO+AngII, n=5). Protein expression of AT1 and AT2 receptor, CD68, and α-actin was measured by immunofluorescence in formalin-fixed, paraffin-embedded aorta tissue. ANOVA and Kruskal Wallis tests were used to compare the average fluorescent intensity between groups. Results: AngII treatment was associated with increased AT1 receptor expression in a WT group, but not with AT2 receptor expression (vs. WT+SAL,p=0.06 and p=0.31, respectively). The ELA-2KO group showed no difference in AT1 receptor expression in a response to AngII infusion compared to a ELA-2KO+SAL group (p=0.81). While ELA-2KO+Ang II mice had lower AT2 expression compared to ELA-2KO+SAL (p=0.05). The α-actin expression was similar in all groups. WT+AngII group expressed more CD68 expression in a response to an AngII treatment that was increased in a WT group (p=0.03), but not in a ELA-2KO group. Conclusion: Our data demonstrate that Ang II treatment did not increase an expression of AT1 receptor in ELA-2KO, but was associated with a downregulation of AT2 receptors. Taken together, this suggests That ELA-2KO mice resistance to developing an aorta dilation/AAA is related to downregulation of Ang II receptors. Our results also highlight the importance of the local/tissue response in the pathophysiology of AAA.
Abstract P102: A History Of Preeclampsia Is Associated With Accelerated Aging And Multimorbidity Later In Life
Background: Preeclampsia (PE) is a pregnancy-specific hypertensive disorder which affects up to 7% of all pregnancies. It is associated with increased risk for cardiovascular disease later in life. We have recently reported increased senescence and accelerated aging in women with PE. We hypothesize that senescence burden remains after PE. The aim of this study was to compare senescence profiles, and history of individual chronic conditions and multimorbidity, a marker of accelerated aging, in women with and without a history of PE. Methods: Forty women with histories of PE and 40 with histories of normotensive pregnancy confirmed by manual chart review were age- and parity-matched. None of the women had a history of CVD at the time of recruitment. Markers of senescence (p16, p21 and Klotho) and metabolic syndrome (leptin, adiponectin) were measured and compared between women with and without histories of preeclampsia using conditional logistic regression. The rates of chronic conditions and multimorbidity between the groups were also compared. Results: Urinary Klotho/creatinine levels were significantly lower (median [IQR]: 117 [87.4, 224] vs. 205 [101, 359], respectively, p=0.042), while leptin/adiponectin ratio was significantly higher (median [IQR]: 0.25 [0.13, 0.45] vs. 0.05 [0.02, 0.12], p=0.027) among women with histories of PE compared to controls. There were no significant differences observed in plasma p21 or p16 concentrations. Women with histories of PE experienced a higher prevalence of two or more co-morbidities compared to women with normotensive pregnancies [67.5% (27/40) vs. 22.5% (9/40), p<0.05]. Results were similar after removing hypertension as a comorbidity [45% (18/40) vs. 20.0% (8/40), p<0.05]. Conclusion: Women with a history of PE had altered markers of senescence, metabolic syndrome and multimorbidity decades after PE.
Abstract P006: Systematic Identification Of Metabolites Associated With Manp, A Novel Anp Analog, In Human Hypertension With Metabolic Syndrome
Introduction: The atrial natriuretic peptide (ANP) regulates blood pressure (BP) and cardiorenal homeostasis via activation of guanylyl cyclase A (GC-A) receptor and second messenger cGMP. We recently demonstrated the safety, tolerability, and BP-lowering properties of MANP, an ANP analog and best-in-class GC-A activator, in subjects with essential hypertension (HTN). However, the effects of MANP on human metabolome during HTN remains undefined. Hypothesis: A single subcutaneous (SQ) administration of MANP can trigger metabolomic changes in humans. Methods: Twenty-two patients with HTN and metabolic syndrome (MetS) were randomized to receive placebo (N=5) or MANP (N=17, 2.5 μg/kg). Untargeted liquid chromatography mass spectrometry-based metabolomics and informatics were conducted on plasma of all subjects at baseline, 1 h post injection (hpi), and 6 hpi. Top circulating metabolites associated with MANP treatment were identified via a comparison of abundance between before and after MANP administration. Results: Compared to placebo, MANP resulted in the most prominent cGMP increase at 1 hpi and BP lowering effect at 6 hpi. With untargeted approach, we identified totally 1384 circulating metabolites. Principal component analysis supported distinct metabolic signatures at baseline, 1 hpi and 6 hpi in subjects receiving MANP. In MANP group, we found 31 metabolites at 1 hpi and 148 metabolites at 6 hpi showing significant change in abundance (adjusted P value < 0.05) compared to baseline. By contrast, <10 metabolites with difference in circulating abundance at either 1 hpi or 6 hpi compared to baseline were found in placebo group. Specifically, 8 annotated metabolites were identified with significant and progressive changes at both 1 and 6 hpi after treatment of MANP but not placebo, which included spisulosine, paecilaminol, quinine ethyl carbonate, thyrotropin releasing hormone, 3-epideoxycholic acid, hellicoside, pentanorvitamin D3, and tetracosanal. Conclusion: SQ administration of MANP triggers changes in a wide range of circulating metabolites beyond cGMP activation and BP reduction in humans. The biological outcome and clinical impact of these MANP-associated metabolites may help guide a precision medicine approach in HTN with MetS.
BACKGROUND: Management of sporadic schwannomas is often dictated by a patient's clinical presentation and the tumor's behavior. For patients who are managed nonsurgically, there are little data available about the expected natural history. OBJECTIVE: To evaluate the natural history and growth patterns of extracranial schwannomas including tumors of the distal peripheral nerves, spine, and brachial plexus. METHODS: A retrospective review was performed to identify patients with nonsyndromic extracranial schwannomas at a single tertiary care institution diagnosed between 2002 and 2019. Patient data and tumor characteristics including volume were recorded. RESULTS: Two hundred twenty-seven patients were identified (mean age 51 years, 42% male, average of 27.8-month follow-up). Tumor location was distal peripheral nerve in 82, brachial plexus in 36, and paraspinal in 109. At the time of diagnosis, peripheral lesions were significantly larger than spinal (59 m 3 vs 13 cm 3 ) and brachial plexus lesions (15 cm 3 ). Distinct growth patterns were seen with both distal peripheral nerve and spinal lesions; 34/82 peripheral nerve lesions had fast growth (β = 0.176%/day), and 48 had slow growth (β = 0.021%/day; P < .01). Spinal schwannomas similarly had 30 fast-growing (β = 0.229%/day), 16 moderate-growing (β = 0.071%/day), and 63 slow-growing (β = 0.022%/day; P = .03) subtypes. The brachial plexus had relatively homogeneous growth patterns (β = 0.065%/day). Females had 2.9 times greater odds of having the fast-growing subtype. CONCLUSION: Distinct growth patterns were seen in extracranial sporadic schwannomas based on tumor location and patient demographics. Fast (>80% volume change per year) vs slow (5%-10% per year) tumor growth can often be ascertained within 2 follow-up images. Awareness of these patterns might have implications for patient counseling and therapeutic decision-making.